Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus

Investigative Radiology

Volumn 51, Issue 5, 2016, Pages 273-279

  Runge, Val M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cerebellar nuclei; Contrast media; Dentate nucleus; Gadobenate dimeglumine; Gadodiamide; Gadolinium based contrast agents; Gadopentetate dimeglumine; Gadoversetamide; Magnetic resonance; Safety; Toxicity

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; CONTRAST MEDIUM;

CHRONIC KIDNEY FAILURE; DENTATE NUCLEUS; DISSOCIATION; DRUG ACCUMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSTRUMENT STERILIZATION; METABOLIC STABILITY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN; CEREBELLUM NUCLEUS; CHEMISTRY; DRUG STABILITY; METABOLISM; PROCEDURES;

ANIMALS; BRAIN; CEREBELLAR NUCLEI; CONTRAST MEDIA; DRUG STABILITY; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84960194105     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000273     Document Type: Review

References (72)

1. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weightedMR images: relationshipwith increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834-841.
2. RadbruchA,Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783-791.
3. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275:803-809.
4. Errante Y, Cirimele V,Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patientswith normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685-690.
5. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782.
6. Quattrocchi CC, MallioCA, ErranteY, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470-472.
7. Radbruch A,Weberling LD, Kieslich PJ, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805-810.
8. Cao Y, Huang DQ, Shih G, et al. Signal change in the dentate nucleus on T1- weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol. 2015;206:414-419.
9. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015;50:743-748.
10. Ramalho J, Castillo M, AlObaidy M, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology. 2015;276:836-844.
11. Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1Wmagnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2016;26:807-815.
12. Treinen KA, Gray TJ, Blazak WF. Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague-Dawley rats. Teratology. 1995; 52:109-115.
13. Hao D, Ai T, Goerner F, et al. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging. 2012;36:1060-1071.
14. Runge VM. Allergic reactions to gadolinium chelates. AJR Am J Roentgenol. 2001;177:944-945.
15. Runge VM, Parker JR.Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol. 1997;7(suppl 5):243-245.
16. Morgan DE, Spann JS, Lockhart ME, et al. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. Radiology. 2011; 259:109-116.
17. Runge VM, Stewart RG, Clanton JA, et al. Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology. 1983;147:789-791.
18. Runge VM, Ai T, Hao D, et al. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011; 46:807-816.
19. CacherisWP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes.Magn Reson Imaging. 1990;8:467-481.
20. Frenzel T, Lawaczeck R, Taupitz M, et al. Contrast media for x-ray and magnetic resonance imaging: development, current status and future perspectives. Invest Radiol. 2015;50:671-678.
21. PortM, Idee JM,Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
22. Bonnemain B, Meyer D. Present aspects ofMRI contrast agents. Early experience with DOTA gadolinium. MR'85. Internationales Kernspintomographie Symposium. Garmisch-Partenkirchen. Schnetztor-Verlag GmbH Konstanz. 1985:81-88.
23. Runge VM, Bradley WG, Brant-Zawadzki MN, et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology. 1991;181:701-709.
24. Tweedle MF, Eaton SM, Eckelman WC, et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol. 1988;23(suppl 1): S236-S239.
25. Tweedle MF, Gaughan GT, Hagan J, et al. Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. Int J Rad Appl Instrum B. 1988;15:31-36.
26. Wedeking P, Tweedle M. Comparison of the biodistribution of 153Gd-labeled Gd (DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice. Int J Rad Appl Instrum B. 1988;15:395-402.
27. Meyer D, Schaefer M, Bonnemain B. Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge. Invest Radiol. 1988;23(suppl 1): S232-S235.
28. Runge VM. Chapter 9, nonionic gadolinium chelates, Glen Gaughan. In: Enhanced Magnetic Resonance Imaging. St Louis, MO: CV Mosby; 1989:108.
29. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582.
30. Niendorf HP, Dinger JC, Haustein J, et al. Tolerance data of Gd-DTPA: a review. Eur J Radiol. 1991;13:15-20.
31. Puttagunta NR, GibbyWA, Puttagunta VL. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol. 1996;31:619-624.
32. Tweedle MF. Using radiotracers to characterize magnetic resonance imaging contrast agents. Invest Radiol. 2002;37:107-113.
33. Runge VM, Kuehl TJ, Jackson CB, et al. Subchronic toxicity of the gadolinium chelates. Acad Radiol. 2005;12(suppl 1):S6-S9.
34. Harpur ES,Worah D, Hals PA, et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993;28(suppl 1):S28-S43.
35. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest. 1995;55:421-426.
36. Lin J, Idee JM, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal. 1999;21:931-943.
37. Lowe A, Balzer T, Hirt U. Interference of gadolinium-containing contrastenhancing agents with colorimetric calcium laboratory testing. Invest Radiol. 2005;40:521-525.
38. Fretellier N, Poteau N, Factor C, et al. Analytical interference in serum iron determination reveals iron versus gadolinium transmetallation with linear gadoliniumbased contrast agents. Invest Radiol. 2014;49:766-772.
39. PrinceMR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003;227:639-646.
40. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
41. Khurana A, Runge VM, NarayananM, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145.
42. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007; 80:73-76.
43. Rydahl C, Thomsen HS,Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadoliniumcontaining magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
44. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
45. SieberMA, Pietsch H,Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
46. Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:200-207.
47. Fretellier N, Idee JM, Dencausse A, et al. Comparative in vivo dissociation of gadoliniumchelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011; 46:292-300.
48. Idee JM, Fretellier N, Robic C, et al. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Crit Rev Toxicol. 2014; 44:895-913.
49. Rowe PS, Zelenchuk LV, Laurence JS, et al. Do ASARM peptides play a role in nephrogenic systemic fibrosis? Am J Physiol Renal Physiol. 2015;309:F764-F769.
50. Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2. Acta Radiol. 2016.
51. Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1. Acta Radiol. 2016.
52. Amet S, Launay-Vacher V, Clement O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogenique Systemique study. Invest Radiol. 2014;49:109-115.
53. Lauenstein T, Ramirez-Garrido F, Kim YH, et al. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol. 2015;50:416-422.
54. Bruce R, Wentland AL, Haemel AK, et al. The incidence of NSF using gadobenate dimeglumine in 1423 patients with renal insufficiency compared to gadodiamide. Invest Radiol. 2016;51.
55. Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015;50:473-480.
56. Robert P, Violas X, Grand S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol. 2016;51:73-82.
57. Jost G, Lenhard DC, Sieber MA, et al. Signal increase on unenhanced T1- weighted images in the rat brain after repeated, extended doses of gadoliniumbased contrast agents: comparison of linear andmacrocyclic agents. Invest Radiol. 2016;51:83-89.
58. Tweedle MF, Gaughan GT, Hagan JT. 1-substituted-1,4,7-triscarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs. US Patent 4885363. Jan 23, 1986.
59. Huckle JE, Altun E, Jay M, et al. Gadolinium deposition in humans: when did we learn that gadolinium was deposited in vivo? Invest Radiol. 2016;51:236-240.
60. Roberts DR, Lindhorst SM, Welsh CT, et al. High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol. 2016; 51:280-289.
61. Barbieri S, Schroeder C, Froehlich JM, et al. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. Contrast Media Mol Imaging. 2016.
62. Popescu BF, Robinson CA, Rajput A, et al. Iron, copper, and zinc distribution of the cerebellum. Cerebellum. 2009;8:74-79.
63. Koeppen AH, Ramirez RL, Yu D, et al. Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. Cerebellum. 2012;11:845-860.
64. Birka M, Wentker KS, Lusmoller E, et al. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem. 2015;87:3321-3328.
65. Feng L, Xiao H, He X, et al. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol Lett. 2006;165:112-120.
66. Thomsen HS. T1 hyperintensity in the brain after multiple intravenous injections of gadolinium-based contrast agents. Acta Radiol. 2016.
67. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
68. Shen Y, Goerner FL, Snyder C, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 2015;50:330-338.
69. Runge VM. Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015;50:481-482.
70. RungeVM.Gadoliniumand nephrogenic systemic fibrosis. AJR AmJ Roentgenol. 2009;192:W195-W196.
71. Runge VM. Macrocyclic versus linear gadolinium chelates. Invest Radiol. 2015; 50:811.
72. Malayeri AA, Brooks KM, Bryant LH, et al. National Institutes of Health perspective on reports of gadolinium deposition in the brain. J Am Coll Radiol. 2016.